Want to see AU:ENP full AI Analyst Report?

Tryptamine Therapeutics (ENP) Price & Analysis

19 Followers

ENP Stock Chart & Stats

AU$0.04

Market closed

AU$0.04

Day’s Range― - ―

52-Week RangeAU$0.03 - AU$0.04

Previous CloseN/A

VolumeN/A

Average Volume (3M)1.26M

Market Cap

AU$50.66M

Enterprise ValueAU$48.24M

Total Cash (Recent Filing)AU$5.58M

Total Debt (Recent Filing)AU$0.00

Price to Earnings (P/E)―

Beta0.45

Next Earnings

Feb 26, 2027

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)>-0.01

Shares Outstanding1,634,217,200

10 Day Avg. Volume830,028

30 Day Avg. Volume1,264,318

Financial Highlights & Ratios

PEG Ratio0.50

Price to Book (P/B)6.82

Price to Sales (P/S)0.00

P/FCF Ratio-14.72

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.02

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Debt-Free Balance SheetPositive equity and the absence of reported debt reduce refinancing and interest-rate exposure, giving the company greater financial flexibility while its therapeutic programs advance. This balance-sheet position can help preserve strategic options over the next several quarters, despite ongoing cash needs.

Improving Net LossThe smaller annual loss indicates some cost containment and offers an early sign that spending may be becoming more disciplined. If maintained while development programs progress, this improvement could extend the company’s funding runway and reduce the pace at which additional capital is required.

Growing Asset And Equity BaseGrowth in total assets alongside higher equity strengthens the company’s current financial foundation relative to the prior year. While this does not establish commercial success, it provides more resources to support research and development and may improve resilience as programs move forward.

Bears Say

No Recurring RevenueThe absence of meaningful recurring revenue leaves the company dependent on capital markets or other funding sources rather than internally generated business income. Until a therapy is commercialized, the lack of revenue limits financial self-sufficiency and makes progress vulnerable to funding constraints.

Persistent Operating LossesSustained operating and net losses show that the business has not yet developed a profitable economic model. Continued investment may be necessary to advance its pipeline, but without revenue growth or a clear path to profitability, losses can weigh on financial flexibility across the next several quarters.

Ongoing Cash BurnNegative operating and free cash flow demonstrate that reported losses are translating into real cash usage rather than being mainly non-cash charges. Even with sharply lower outflows in 2026, continued burn can require external funding and may create dilution risk if development spending persists.

Tryptamine Therapeutics News

Entropy Neurodynamics Boosts Director Equity Through Share-Based Fees

An announcement from Tryptamine Therapeutics ( ($AU:ENP) ) is now available. Entropy Neurodynamics Limited has disclosed a change...

17d ago

ENP

Entropy Neurodynamics Issues Director Fee Shares, Confirms Regulatory Compliance

Tryptamine Therapeutics ( ($AU:ENP) ) just unveiled an announcement. Entropy Neurodynamics Limited has issued 623,441 fully paid ordinary...

17d ago

ENP

Entropy Neurodynamics Issues Equity to Directors in Lieu of Cash Fees

The latest announcement is out from Tryptamine Therapeutics ( ($AU:ENP) ). Entropy Neurodynamics Limited, an ASX-listed company in...

17d ago

ENP

Entropy Neurodynamics posts 2026 AGM materials and streamlines investor communications

Tryptamine Therapeutics ( ($AU:ENP) ) has provided an update. Entropy Neurodynamics Limited has released key documents for its...

26d ago

ENP

Entropy Neurodynamics Sets Date for 2026 AGM and Director Nomination Deadline

The latest update is out from Tryptamine Therapeutics ( ($AU:ENP) ). Entropy Neurodynamics Limited has scheduled its 2026...

2M ago

ENP

Entropy Neurodynamics Reports Durable 12-Week Gains in BED Trial of Psychedelic Therapy TRP-8803

Tryptamine Therapeutics ( ($AU:ENP) ) has shared an update. Entropy Neurodynamics Limited, a clinical-stage biotech in Melbourne, is...

2M ago

ENP

Entropy Neurodynamics to Showcase Psilocin Program in Investor Webinar

Tryptamine Therapeutics ( ($AU:ENP) ) has shared an update. Entropy Neurodynamics Limited, a clinical-stage biotech focused on psilocin-based...

2M ago

ENP

Entropy Neurodynamics Files ASX Governance Disclosures for 2026

Tryptamine Therapeutics ( ($AU:ENP) ) just unveiled an update. Entropy Neurodynamics Limited has lodged its Appendix 4G and...

2M ago

ENP

Entropy Neurodynamics Narrows Annual Loss as Revenue Jumps 30%

Tryptamine Therapeutics ( ($AU:ENP) ) has issued an update. Entropy Neurodynamics Limited operates in the neurodynamics and therapeutics...

2M ago

ENP

Entropy Neurodynamics Plans U.S. Phase 2 Trial Pitting Psychedelic Therapy Against Lexapro

Tryptamine Therapeutics ( ($AU:ENP) ) just unveiled an announcement. Entropy Neurodynamics has signed a pre-Clinical Trial Agreement with...

2M ago

ENP

ENP FAQ

What was Tryptamine Therapeutics Limited’s price range in the past 12 months?

Tryptamine Therapeutics Limited lowest share price was AU$0.03 and its highest was AU$0.04 in the past 12 months.

What is Tryptamine Therapeutics Limited’s market cap?

Tryptamine Therapeutics Limited’s market cap is AU$50.66M.

When is Tryptamine Therapeutics Limited’s upcoming earnings report date?

Tryptamine Therapeutics Limited’s upcoming earnings report date is Feb 26, 2027 which is in 118 days.

How were Tryptamine Therapeutics Limited’s earnings last quarter?

Tryptamine Therapeutics Limited released its earnings results on Aug 27, 2026. The company reported -AU$0.001 earnings per share for the quarter.

Is Tryptamine Therapeutics Limited overvalued?

According to Wall Street analysts Tryptamine Therapeutics Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Tryptamine Therapeutics Limited pay dividends?

Tryptamine Therapeutics Limited does not currently pay dividends.

What is Tryptamine Therapeutics Limited’s EPS estimate?

Tryptamine Therapeutics Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Tryptamine Therapeutics Limited have?

Tryptamine Therapeutics Limited has 1,634,217,200 shares outstanding.

What happened to Tryptamine Therapeutics Limited’s price movement after its last earnings report?

Tryptamine Therapeutics Limited reported an EPS of -AU$0.001 in its last earnings report. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Tryptamine Therapeutics Limited?

Currently, no hedge funds are holding shares in AU:ENP

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Tryptamine Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-63.60%

Trailing 12-Months

Asset Growth

25.83%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Tryptamine Therapeutics Limited

Entropy Neurodynamics Limited operates as a clinical-stage pharmaceutical company, dedicated to pioneering novel formulations for psilocin administration. These formulations are intended for use alongside psychotherapy, aiming to tackle medical conditions with pressing unmet needs across Australia, Canada, Switzerland, and the United States. The firm's flagship development is TRP-8803, an intravenously infused psilocin formulation that has successfully concluded Phase 2 clinical trials. These trials investigated its potential to treat binge eating disorder, fibromyalgia, irritable bowel syndrome, abdominal pain, and visceral tenderness. Additionally, the company is advancing TRP-8802, a synthetic, orally administered psilocybin compound. TRP-8802 is currently undergoing Phase 2a clinical trials for binge eating and is in Phase 2 clinical development for fibromyalgia and irritable bowel syndrome. Established in 2019 and headquartered in Camberwell, Australia, the company adopted its current name, Entropy Neurodynamics Limited, in November 2025, having previously operated as Tryptamine Therapeutics Limited.